The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART

• Published in: Frontiers in immunology Vol. 10; p. 2911
• Main Authors: Haidari, G., Day, Suzanne, Wood, M., Ridgers, H., Cope, Alethea V., Fleck, Sue, Yan, Celine, Reijonen, Kalevi, Hannaman, Drew, Spentzou, Aggeliki, Hayes, Peter, Vogt, A., Combadiere, Behazine, Cook, Adrian, McCormack, Sheena, Shattock, Robin J.
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers 13.12.2019; Frontiers Media S.A
• Subjects: Administration, Cutaneous; AIDS Vaccines - administration & dosage; AIDS Vaccines - adverse effects; AIDS Vaccines - immunology; Antiretroviral Therapy, Highly Active; Cytokines - metabolism; Electroporation; HIV Infections - drug therapy; HIV Infections - immunology; HIV Infections - prevention & control; HIV-1; HIV-1 - immunology; Humans; Immunogenicity, Vaccine; Immunology; Injections, Intramuscular; Life Sciences; Patient Outcome Assessment; plasmid DNA; therapeutic vaccine; transcutaneous; Vaccination; Vaccines, DNA - administration & dosage; Vaccines, DNA - adverse effects; Vaccines, DNA - immunology; Vaccinology; HIV-1; therapeutic vaccine; plasmid DNA; electroporation; transcutaneous
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2019.02911

Previous studies have shown targeting different tissues via the transcutaneous (TC) and intramuscular injection (IM) with or without electroporation (EP) has the potential to trigger immune responses to DNA vaccination. The CUTHIVTHER 001 Phase I/II randomized controlled clinical trial was designed...